 Can-Fite BioPharma Ltd. NYSE American: CANF TASE:CFBI, a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 3,902,440 of the Companys American Depositary Shares ADSs, at a purchase price of 2.05 per ADS, in a registered direct offering. Can-Fite has also agreed to issue and sell to the investors, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 1,951,220 ADSs. Each ADS represents thirty 30 ordinary shares, par value NIS 0.25 per share, of Can-Fite. The offering is expected to close on or about June 12, 2020, subject to satisfaction of customary closing conditions. 